All > Paid Studies Houston > Chordoma

Cetuximab for Chordoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Chordoma+2 MoreCetuximab - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to treat chordoma, a type of cancer. The target patient population is any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.

Eligible Conditions
  • Chordoma
  • Metastatic Chordoma
  • Unresectable Chordoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Infigratinib
1
Cetuximab
1
Cetuximab

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year

Year 1
Overall response rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Infigratinib
1
Cetuximab
1
Cetuximab

Side Effects for

Cetuximab + Cisplatin + 5-FU : Treatment Emergent Phase
43%Leucopenia
43%Weight Decreased
40%Nausea
35%Rash
34%Hypomagnesaemia
32%Hypokalemia
31%Constipation
28%Neutropenia
28%Vomiting
26%Decreased Appetite
22%Pyrexia
19%Hyponatremia
19%Hemoglobin Decreased
19%Acne
18%Diarrhea
18%Stomatitis
15%Fatigue
15%Pruritus
13%Mucosal Inflammation
13%Neutrophil Count Decreased
12%Mouth Ulceration
10%Thrombocytopenia
10%Asthenia
10%Insomnia
9%Cough
9%White Blood Cell Count Decreased
9%Dizziness
7%Abdominal Pain Upper
7%Aspartate Aminotransferase Increased
7%Paronychia
7%Hypochloremia
7%Weight Increased
7%Hypocalcaemia
7%Dermatitis Acneiform
6%Oral Pain
6%Headache
6%Neck pain
6%Dyspnoea
3%Anaphylactic reaction
1%Pulmonary embolism
1%Toxic encephalopathy
1%Myocardial infarction
1%Staphylococcal skin infection
1%Microcytic anemia
1%Electrolyte imbalance
1%Tumor hemorrhage
1%Pneumonia
1%Mouth hemorrhage
1%Pneumonitis
1%Venous thrombosis
1%Respiratory alkalosis
This histogram enumerates side effects from a completed 2012 Phase 3 trial (NCT01177956) in the Cetuximab + Cisplatin + 5-FU : Treatment Emergent Phase ARM group. Side effects include: Leucopenia with 43%, Weight Decreased with 43%, Nausea with 40%, Rash with 35%, Hypomagnesaemia with 34%.

Trial Design

1 Treatment Group

Treatment (cetuximab)
1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Cetuximab · No Placebo Group · Phase 2

Treatment (cetuximab)Experimental Group · 2 Interventions: Cetuximab, Questionnaire Administration · Intervention Types: Biological, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cetuximab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,805 Previous Clinical Trials
1,790,364 Total Patients Enrolled
2 Trials studying Chordoma
83 Patients Enrolled for Chordoma
Anthony P ConleyPrincipal InvestigatorM.D. Anderson Cancer Center
Anthony P Conley, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a histologically confirmed diagnosis of chordoma which is advanced (unresectable) and/or metastatic.
Patients may have any prior line of therapy, but there should a washout period of at least 3 weeks from any systemic therapy (small molecule/targeted agents, immunotherapies) and/or radiation therapy.
You are recovering from any prior therapy.
A new tumor related biopsy should be considered within acceptable risk to the patient.
At least one site of measurable disease on x-ray/CT/MRI and/or PET/CT scan as defined by RECIST 1.1 criteria
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top